Brainstorm Cell Therapeutics Inc.
BCLI
$1.22
$0.010.83%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -26.81% | -2.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.63% | 2.21% | |||
| Operating Income | -4.63% | -2.21% | |||
| Income Before Tax | -9.79% | -6.57% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.79% | -6.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.79% | -6.57% | |||
| EBIT | -4.63% | -2.21% | |||
| EBITDA | -4.92% | -2.43% | |||
| EPS Basic | -2.12% | 4.71% | |||
| Normalized Basic EPS | -2.10% | 4.69% | |||
| EPS Diluted | -2.12% | 4.71% | |||
| Normalized Diluted EPS | -2.10% | 4.69% | |||
| Average Basic Shares Outstanding | 7.50% | 11.84% | |||
| Average Diluted Shares Outstanding | 7.50% | 11.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||